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Abstract 
 
The etiological spectrum of ultra-rare developmental disorders remains to be fully 
defined. Chromatin-regulatory mechanisms maintain cellular identity and function, 
where misregulation may lead to developmental defects. Here, we report pathogenic 
variations in MSL3, which encodes a member of the chromatin-associated MSL-
complex responsible for bulk Histone 4 Lysine 16 acetylation (H4K16ac) in flies and 
mammals. These variants cause a novel X-linked syndrome affecting both sexes. 
Clinical features of the syndrome include global developmental delay, progressive 
gait disturbance and recognizable facial dysmorphism. MSL3 mutations affect MSL-
complex assembly and activity, accompanied by a pronounced loss of H4K16ac 
levels in vivo. Patient-derived cells display global transcriptome alterations of 
pathways involved in morphogenesis and cell migration. Finally, we use histone-
deacetylase inhibitors to rebalance acetylation levels alleviating some of the 
molecular and cellular phenotypes of patient cells. Taken together, we characterize a 
novel syndrome allowing us to decipher the developmental importance of MSL3 in 
humans. 
 
 
 
Introduction 
 
Recent advances in whole-exome sequencing have led to discovery of numerous 
causative genes for human diseases. However, gathering a large number of patients 
represents a significant bottleneck for gene identification and appropriate molecular 
analysis of rare developmental diseases. Mutations of epigenetic regulators were 
found to cause neurodevelopmental disorders through mechanisms potentially 
altering the chromatin landscape1. To date, over forty Mendelian disorders have 
been identified, which are caused by mutations of the epigenetic machinery and are 
associated with neurological dysfunction, with 80% of them being autosomally 
encoded2–4. Fluctuations in the histone acetylation balance, due to the interplay 
between acetylase and deacetylase functions during development, contributes to the 
final shape and performance of the adult brain and the whole organism5–8. Whilst 
several modifications within the histone core were found to alter chromatin 
architecture9, Histone 4 Lysine 16 acetylation (H4K16ac) appears uncommon 
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amongst the tail modifications as it directly affects higher order chromatin structure10. 
The Male Specific Lethal (MSL) complex-associated MOF/KAT8 histone acetyl-
transferase is responsible for bulk H4K16ac in flies and mammals11. Given its crucial 
importance, we know surprisingly little about the role of MSL-mediated H4K16ac 
during development and whether its misregulation is associated with any disease in 
humans. 
 
Results 
 
Mutations in MSL3 cause a novel neurodevelopmental disorder 
Through the international Matchmaker Exchange Initiative12, we have identified de 
novo variants in MSL3 (Male Specific Lethal homolog 3 Homolog, previously known 
as MSL3L1, Refseq gene NG_012564.1) in fifteen unrelated families from Europe, 
the US and Australia (Figures 1a, 1b, Supplementary Figure 1a). In the matchmaking 
cohort we identified eleven truncating variants (p1-3, p5-11, p13), one exon deletion 
(p12), one missense variant (p4), two gene-deletions (p14-15) and one chromosomal 
inversion (p16) (Figure 1c, Table 1). Patients 1 to 9 were gathered from a cohort of 
approximately 10,000 individuals with intellectual disability, demonstrating a 
significant enrichment for MSL3 de novo truncating variants in this cohort compared 
to random occurrence (uncorrected p-value = 8.98e-16, pFDR = 1.64e-11) 
(Supplementary Figure 1b-c, Table 1). The enrichment for truncating variants in this 
cohort of patients is consistent with the data from the ExAC database, suggesting 
that MSL3 is extremely intolerant to loss-of-function variations (pLI=0,95)13. For 
patients 5 and 6 (monozygotic twins), deep sequencing of leucocyte parental DNA 
did not detect an alternative allele. Patient 16 inherited the X-inversion causing a 
putative in-frame transcript between MSL3 and GAB3 from his mildly affected mother 
(Table 1 and Supplementary Figure 1d). 
MSL3 is known for its role during X chromosome dosage compensation via H4K16ac 
in Drosophila. Its absence affects male flies and manifests in lethality in the last 
larval stage of development11,14,15. The human MSL3 gene resides on the X 
chromosome and its mutations presented here affect both hemizygous male and 
heterozygous female individuals (Figure 1a, Supplementary Table 1). Common 
features across the 16 patients include hypotonia, feeding difficulties in early infancy 
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and global delay in the acquisition of major milestones including walking and speech. 
Intellectual disability was also scored. The phenotypic spectrum is more 
homogeneous across patients of both sexes with single nucleotide variants (SNVs) 
compared to patients with chromosomal rearrangements. The patients with SNVs 
display progressive spasticity or an ataxic gait (9/13), resulting in inability to walk 
(5/13). The facial morphology is strongly overlapping across patients with 
telecanthus (8/13), epicanthal folds (9/13), down-slanting palpebral fissures (9/13), 
downturned corners of the mouth (8/13) and dysplastic ears (11/13) (Figure 1b, 
Supplementary Table 1, also see the detailed clinical descriptions in Supplementary 
Note 1). Altogether, these clinical observations delineate a recognizable MSL3 
syndrome. In line with these phenotypes, MSL3 is ubiquitously expressed in the 
developing human brain until 17-20 weeks post conception. Other MSL complex 
members display a similar expression pattern, though their RNA levels seem slightly 
higher (Supplementary Figure 1e16). 
Most of the pathogenic MSL3 variants affect the C-terminal MRG domain (Figure 1d, 
Supplementary Figure 1f), which is responsible for MSL complex formation while 
enhancing the activity of MOF towards H4K16ac (Figure 1e,17,18). 
Using in silico modeling of the crystal structure of the human MSL3-MSL1 complex17, 
we predicted that the truncations present in the patients impair the integration of 
mutant MSL3 into the MSL complex (Figure 1f, g). To test this, we transiently 
transfected expression vectors encoding wild-type (full-length) and three different 
MSL3 mutants, representing patients 1, 2 and 3 (p1, p2, p3) into Flp-In T-REx 293 
cells. We observed that in contrast to wild-type MSL3, which showed robust 
interaction with MSL1 and MOF, all three mutants lost the interaction with MOF and 
to a lesser extent with MSL1 (Figure 1h, lanes 6-9). Two of the mutations also 
decreased MSL3 protein stability (Figure 1h, lanes 2 and 3). Taken together, we find 
that the mutations present in the patients with MSL3 syndrome lead to severely 
compromised MSL complex integrity. 
 
Bulk reduction of H4K16 acetylation in MSL3 patient cells  
To characterize the molecular consequences of MSL3 mutations in patients, we 
obtained skin biopsies from two female patients harboring frameshift mutations (p1 
and p2), one female patient with a locus deletion (p14) and one control tissue (ctrl) 
from p1’s healthy mother. In addition, we analysed two more skin biopsies from 
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healthy donors as controls (see Methods). These samples were used to perform 
histological analyses and establish primary dermal fibroblast cell culture models for 
all molecular analyses presented below. 
Hematoxylin and Eosin staining confirmed that the overall tissue architecture was 
preserved in both control and patient specimens (Supplementary Figure 2a). The 
MSL complex is responsible for bulk H4K16ac in flies19,20 and mammalian cell 
culture models14,15,21. Based on this, we performed immunostaining of H4K16ac in 
patient samples compared to skin punches of controls. While the H4K16ac staining 
had homogeneous intensity in dermal and epidermal layers of all three control 
samples, MSL3 patient cells showed a heterogeneous pattern with a marked and 
variable reduction in H4K16ac (Figure 2a, asterisks). This striking reduction of 
H4K16ac could result from decreased levels of MOF in MSL3 patient cells. However, 
MOF immunostaining displayed a homogenous distribution within all cells of the 
tissue section (Figure 2b). This indicates that the loss of H4K16ac is not caused by 
the reduction in MOF levels per se but rather due to a misregulation of its enzymatic 
activity. 
We confirmed these observations in primary fibroblast cells established from skin 
punches, where cells lacking functional MSL3 also displayed a severe decrease in 
H4K16ac (Figure 2c, d), but not other histone modifications (e.g. H3K27me3, Figure 
2e and Supplementary Figure 2b). Remarkably, quantification of these stainings 
showed a global reduction of H4K16ac in these heterozygous XMSL3-WT/XMSL3-MUT 
female patient samples (Figure 2d). Such a staining pattern is unusual for an X-
linked gene in females, where conventionally, heterozygous mutations would be 
expected to result in a 50:50 population of wild-type and mutant cells. Targeted 
sequencing of MSL3 cDNA for patient 1 and 2 demonstrated the mild co-expression 
of mutated and wild-type allele at the RNA level (Supplementary Figure 2d). While 
the nature of MSL3 mutation in p14 (whole gene deletion) precludes expression of 
any mutated MSL3 protein, we note that p1/2 proteins were highly unstable (Figure 
1h), making it unlikely that the MSL3 syndrome is generally caused by a dominant 
negative effect. However, human MSL3 was recently found to be a facultative 
escapee22, which is stochastically and variably expressed from both female X 
chromosomes. We therefore propose that MSL3 haploinsufficiency might cause the 
variable but consistent reduction of H4K16ac in female patients. 
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Since there could be a potential crosstalk between H4K16ac and other residues on 
the histone tails23 and given that MSL3 has been linked to H3K36me3 and 
H4K20me124,25, we validated the above findings by bulk Western blot analyses and 
quantitative mass spectrometry (LC-MS). In line with the immunofluorescence, we 
exclusively scored a reduction of MSL3 and H4K16ac levels, while MOF and other 
modifications remained unaffected in western blots (Figure 2f, Supplementary Figure 
2c, Supplementary Figure 5). Affirming these results, when comparing the three 
patients to two different controls by comprehensive histone LC-MS analysis, the 
modification that was by far the most significantly affected, both by p-value and fold-
change, was H4K16ac (Figure 2g, Supplementary Figure 2e, f and Supplementary 
Table 2). Hence, loss of MSL3 in patients appears to primarily affect H4K16ac. 
H4K16ac has been previously linked to cell cycle regulation21,26–28. We noticed that 
patient-derived fibroblasts grew significantly slower than control cells 
(Supplementary Figure 2g), nevertheless no clear difference of any specific cell cycle 
phase could be scored (Supplementary Figure 2h). Cells did not show signs of G1/S 
arrest both by qPCR for senescence markers nor by X-Gal staining (Supplementary 
Figure 2i, j). Furthermore, no differences were scored for γH2AX signal, indicating no 
apparent increase in DNA damage (data not shown). 
In order to further dissect the possible cause for the slow growth of female MSL3 
mutant cells, we next challenged them by removal of serum and tested their capacity 
to respond to changes in environmental conditions. Interestingly, upon performing 
these starvation experiments we observed that patient-derived fibroblasts showed a 
delay in exiting G0 phase (Supplementary Figure 2k). This suggests that MSL3 
mutant cells may fail to timely respond to growth factor signals, a property that is 
crucial during development. 
 
Transcriptome deregulation in MSL3 patient cells 
Since MSL3 is part of a chromatin-modifying complex that is involved in transcription 
regulation21,29,30, we next performed RNA-seq experiments on three patient-derived 
primary fibroblast cell lines. For this purpose, we analysed two different passages 
compared to a passage matched control (ctrl) in synchronized conditions. Differential 
expression analysis was performed using DESeq2 and genes with FDR correction 
<0.05 were considered differentially expressed (DE) (Figure 3a). As gene expression 
differences can reflect genetic background or environmental influences between 
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individuals31, we decided to consider only transcripts that were consistently 
deregulated in all three patients. This revealed a set of 519 commonly misregulated 
genes (Figure 3a,b, Supplementary Figure 3a). 
We first explored whether altered expression of these genes could be directly related 
to MSL-mediated H4K16ac. We noticed that the extent of misregulation (log2FC) 
was much more consistent between different patients in the downregulated subset 
compared with the upregulated group of genes (Figure 3a and c). This supports the 
idea that the latter arise from secondary responses within each individual, which may 
be more variable. We also found that the orthologues of the DE-genes in MSL3 
patients were significantly enriched for mMSL2 ChIP peaks in mouse cells21. In 
contrast, mKANSL3 peaks were significantly underrepresented, corroborating the 
hypothesis that the observed effects are caused by H4K16ac deposited by the MSL-, 
but not the KANSL-complex (Figure 3a, d). Therefore, we performed H4K16ac ChIP 
experiments in MSL3 patient cells and focused on conserved mammalian MSL 
targets that are mMSL2-bound in mouse cells and very consistently downregulated 
in both MSL3 patients as well as upon MSL3 knock-down in male and female 
fibroblasts (Figure 3e). These results substantiated our conclusion, as H4K16ac was 
lost from ZNF185 and SPON2, but not H3F3B (Figure 3e, Supplementary Figure 3b). 
We next focused on analyzing the biological functions and pathways orchestrated by 
the DE-genes in MSL3 syndrome. Intriguingly, we found differentially expressed 
Notch-, Hox- and Wnt family members, which are key morphogenetic regulators of 
development from Drosophila to mammals. We confirmed these findings by RT-
qPCR, for which we included several additional control cell lines (ctrl2, ctrl3). 
Remarkably, patient cell lines showed very consistent behavior in the selected set of 
downregulated as well as unaffected control genes (Figure 3f, Supplementary Figure 
3c, Supplementary Table 5). We could also confirm the reduction at the protein level 
for HTR7 and UNC5B in the patient skin specimens (Supplementary Figure 3d). 
Pathway perturbation analysis revealed “Dermatological Diseases”, “Organismal 
Abnormalities”, “Gastrointestinal Disease” as well as “Neurological Disease” as top 
scoring disease signatures (Figure 3g). More specifically, the genes commonly 
affected upon MSL3 mutation are overall involved in the activation of cellular 
movement, the organization of the cytoskeleton or the formation of cell protrusions, 
while mechanisms to reduce cell death are repressed (Figure 3h). These are all 
characteristic symptoms of the MSL3 syndrome underscoring the relevance of our 
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RNA-seq dataset (see Supplementary Table 3 for DE- and clinically relevant genes 
based on MSL3 patient phenotypes). 
We were next interested in dissecting the primary gene expression perturbations 
caused by acute loss of MSL3 versus secondary effects that may accumulate during 
development in the patients. Therefore, we performed MSL3 knock-down 
experiments in control primary fibroblast cell lines as well as MSL3 rescue 
experiments in patient cells to determine the extent to which we could phenocopy the 
gene expression changes detected by RNA-seq. We observed an acute 
downregulation of multiple target genes (e.g. ZNF185, SPON2, NOTCH3, FAM157) 
upon MSL3 knock-down in both male and female cells (Supplementary Figure 3e). 
Genes found to be upregulated in MSL3 patients typically did not respond (e.g. 
PRICKLE) or were sometimes downregulated (WNT2). When we did the inverse 
experiment by providing MSL3 in patient cells, we noted a similar trend (Figure 4a). 
We could rescue several downregulated targets (ZNF185, SPON2, FOSB, EGR2) by 
re-expressing MSL3. Interestingly, these genes were also upregulated in ctrl cells, 
indicating that they might be more generally susceptible to alteration of MSL3 and 
H4K16ac levels. Taken together, our gene expression analysis suggests that lack of 
MSL complex results in acute downregulation of several biologically relevant genes 
including key developmental regulators. This misregulation may then gradually 
trigger secondary perturbances, collectively resulting in the global disease state of 
the MSL3 syndrome. 
 
HDACi-mediated alleviation of phenotypes in patient cells  
Given the clear link between H4K16ac and MSL3 mutation, we considered whether it 
would be possible to not only rescue the phenotypes of patient cells by reintroducing 
MSL3 (Figure 4a) but also by re-adjusting acetylation levels. We therefore tested 
three different classes of histone deacetylase inhibitors (HDACi), which are currently 
approved for Clinical Trial Phase II or III: SAHA (vorinostat)32,33, LBH-589 
(panobinostat)34, MGCD0103 (mocetinostat)35, as well as Trichostatin A (TSA) as a 
positive control36,37. These inhibitors show strong effects on histone H4 acetylation 
and in particular H4K16ac in human transformed cells37 (Supplementary Figure 4a). 
Hence, we referred to the aforementioned study for using HDACi to modulate 
H4K16ac in our primary untransformed cells. 
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Treatment of control and patient cells with HDACi resulted in bulk histone 
hyperacetylation and triggered upregulation of acetylation-sensitive genes 
(Supplementary Figure 4b, c, d). We first verified that the response to HDACi is 
effective in all mutant cells, irrespective of the MSL3/H4K16ac levels. We therefore 
performed immunostainings on HDACi-treated patient cells and observed an overall 
increase of H4K16ac at the single cell level from both MSL3 high and low 
populations (Figure 4b). Quantification of those stainings in patient-derived cells 
confirmed the rescue of H4K16ac, which now was comparable to healthy controls 
(Figure 4c). We next tested whether this has a positive influence on gene 
expression. Remarkably, treatment with HDACi specifically rescued the expression 
level of selected downregulated targets whilst control genes or upregulated targets 
remained largely unchanged (Supplementary Figure 4e and data not shown). In 
contrast to p1, p2 and p14 patient cells responded more selectively to LBH-589 
(panobinostat), while the other two HDACi (SAHA and MGCD0103) showed only a 
modest rescue of gene expression defects (Supplementary Figure 4e). To 
characterize the HDACi response in MSL3 deficient cells in a more comprehensive 
manner, we performed RNA-seq upon treatment with LBH-589. As expected, HDACi 
treatment caused major transcriptional changes (Supplementary Figure 4f and 
Supplementary Table 4). However, we successfully observed previously detected 
pathways, as well as potential side effects of this drug in ctrl and MSL3 patient cells38 
(Figure 4d and Supplementary Table 4). This supports that the primary dermal 
fibroblast cell lines used in our analysis represent a relevant model for studying the 
MSL3 syndrome. 
Interestingly, a large set of the DE-genes reversed their expression towards normal 
levels upon HDACi albeit the extent varied between different genes and patients 
(Supplementary Figure 4g and Supplementary Table 3). We focused our attention on 
the 116 genes which were fully rescued to control levels and hence did not score as 
DE after panobinostat treatment (Figure 4e). Among them, clinically relevant genes 
based on the patient phenotypes were scrutinized. One would expect a positive 
clinical impact by restoring a basal expression of e.g. SOX11 (OMIM:615866), 
HOXD10 (OMIM:142984), LEP (OMIM:164160) or ACTG2 (OMIM:102545) based on 
their role in human disease and patient symptoms including cognitive performances, 
gait disturbance, overweight and feeding difficulties/constipation, respectively. 
Accordingly, KEGG pathway analysis revealed that HDACi may generally rewire 
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deregulated processes relevant to the disease state of MSL3 patients (Figure 4f and 
Supplementary Table 3). 
Hence, we wondered whether we would be able to rescue the previously observed 
cell cycle phenotype and migratory signature using HDACi. Indeed, genes involved 
in G0 arrest, e.g. GAS1, were rescued towards the expression levels in ctrl cells 
upon HDACi (Supplementary Figure 4h), while displaying a slight increase in G1/S 
arrest. Moreover, in agreement with the activation of the respective GO terms 
(Figure 3h), we had observed that MSL3 patient-derived fibroblasts migrate faster 
than ctrl cells. We next assessed whether the positive influence of HDACi on gene 
expression would also lead to a beneficial outcome on a cellular level. Strikingly, 
upon HDACi treatment we could restore the phenotype of MSL3 mutant cells, as 
they now adopted the migratory behavior of the control cells (Figure 4g, h and 
Supplementary Figure 4i). Therefore, HDACi have the potential to both molecularly 
as well phenotypically alleviate at least some of the defects in MSL3 mutant cells, 
thus providing a promising therapeutic avenue for MSL3 patients. 
 
Discussion 
In summary, we report a novel syndrome, where loss of MSL3 is associated with a 
pronounced loss of bulk H4K16ac. The patients presented in our study display a 
complex phenotype including neurodevelopmental delay, with a recurrent facial 
dysmorphism and a progressive neurological disorder. This indicates that MSL-
mediated H4K16ac in humans is involved in the regulation of complex 
developmental processes, for example those occurring in the brain5,39,40. This is 
intriguing as it is in contrast to the sex-specific function of MSL3 during dosage 
compensation in flies, suggesting a more context specific role in mammals. Given 
the conserved role of H4K16ac in chromatin decompaction from yeast to humans, it 
remains to be demonstrated why its physiological roles evolved to be so organism 
specific. Our study also raises a general question on the role of H4K16ac, as MSL3 
patients survive to adulthood compared to the early embryonic lethality of the Mof 
mutant in mouse41–44. An important point to consider in this context is that although 
MSL3 mutations lead to a severe loss of H4K16 acetylation, remaining H4K16ac 
may be sufficient to allow developmental progress to a certain extent, since MOF is 
still expressed in these cells. While no MOF variants have been reported in any 
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developmental disorder yet, de novo heterozygous loss-of-function variants of 
KANSL1 were reported to cause Koolen-de Vries syndrome (KdVS)45–47. KANSL1 
encodes a scaffold component of the MOF-KANSL complex. However, the disease 
characteristics of KdVS are symptomatically and molecularly distinct from MSL3 
patients with regards to features of facial dysmorphism, specifically palpebral 
fissures orientation, nose tip and mouth shape, visceral and brain abnormalities, 
which are absent in the reported MSL3 patients. Although KdVS patients also display 
neuromuscular disorders, the progressive gait disturbance associated with MSL3 
syndrome may be a distinctive feature. Given the multifaceted and widespread roles 
of MOF in processes such as metabolism44, autophagy48 and stress response43, we 
believe that the MSL3 mutations presented here may serve as an elegant 
separation-of-function allele, allowing us to dissect the role of altered H4K16ac 
deposited by the MOF-MSL versus the MOF-KANSL complex during human 
development. 
The MSL3 syndrome affects both hemizygous males and heterozygous females with 
comparable symptoms, which is difficult to reconcile with classical models of X 
chromosomal inheritance49. More recently, it has been appreciated that X-linked 
disorders can display intermediate penetrance, for example due to varying degrees 
of XCI in females50. This includes variations in escape genes, such as IQSEC251, or 
examples like XLH or E1α, where similar phenotypes can be observed in both 
heterozygous females and hemizygous males. For MSL3 this can be presumably 
linked to its property of being a facultative escapee, where various degrees of XCI 
and escape might provide an explanation for the phenotypic and molecular 
differences amongst female MSL3 patients. This is notable for the mother of p16, 
which is a carrier of the disease-causing allele, but is only mildly affected. The nature 
of the MSL3 variants, as well as environmental effects modulating epigenome 
plasticity might additionally contribute to the phenotypic outcome of the syndrome. A 
comprehensive assessment of the allele-specific expression of MSL3 in different 
types of tissues and the establishment of alternative cellular and animal models will 
be required to dissect the apparently very complex regulation and phenotypic 
outcome in MSL3 syndrome in both sexes. 
Lastly, the positive outcome of HDACi partially alleviating migratory and cell cycle 
defects provides a preliminary, yet promising ground for future studies, especially in 
light of the degenerative nature of the MSL3 syndrome. More efforts will need to be 
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undertaken to potentially ameliorate the symptomatology and delay the likely 
myelopathy-caused hyperreflexia, for which HDACi have already shown positive 
results52. The possibility of alleviating at least some of the symptoms of MSL3 
patients through anti-cancer drug repurposing, provides yet another case where 
epigenetic therapy using HDACi may pave ways for treatments of other diseases 
affecting epigenetic modifiers. Taken together, our characterization of this novel 
syndrome not only provides insights into the developmental roles of MSL-associated 
H4K16ac in humans but also underscores the general relevance of studying sex-
specific aspects related to X-linked diseases.  
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Figure Legends 
 
Figure 1 
Mutations in MSL3 cause a novel neurodevelopmental disorder 
(a) MSL3 patient photographs. Grey circles indicate intra-genic variants, yellow 
whole-gene deletions, stars donated skin biopsies. Written consent for the use of 
photographs was obtained from the parents of affected individuals. (b) Human 
Phenotype Ontology heatmap of MSL3 patient common clinical features. Blank 
boxes represent either absent or not reported symptoms. (c) MSL3 locus and 
identified variants highlighted in red. p1-13 variants occur within MSL3 (top), p13/p14 
deletions span ARHGAP6, MSL3 and FRMD4 (middle). p16 chromosomal inversion 
and breakpoints (green) are between Xp22.2 and Xq28 (bottom). (d) Annotation of 
the pathogenic variants on the primary protein structure. Grey lines represent 
predicted proteins, where most SNVs, except for p.(L308P) shown as green dot, 
result in MRG-domain truncation. (e) Cropped H4K16ac and H3 immunoblot of a 
histone acetyltransferase (HAT) assay performed on nucleosomal substrate with the 
indicated proteins (fl=full length (2-458), HAT domain (174-458)). The right panel 
(lanes 2-5) is a coomassie-stained gel of the assayed proteins. The experiment was 
repeated twice with similar results. (f) Modelled surface representation of the MSL1-
MSL3 complex (PDB: 2YON, MSL1:yellow, MSL3:grey/purple). Missing parts in p1 
are highlighted in purple (left) or removed (right). (g) Cartoon representing the MSL1 
(575-585, yellow) and MSL3 (253-270/459-484, grey) interaction interface with 
hydrogen bonds in black. α-helices5/6 missing in p1 are shaded blue. (h) Flag-co-
immunoprecipitations (IP) of MSL3 full-length (fl), MSL3 variants (p2, p1 and p3) 
GFP IP-control with cropped immunoblots. MSL3 and MSL1-HA expression vectors 
were transiently co-transfected into HEK293 cells. DHX9 serves as input loading 
control. The experiment was repeated 4 times with similar results. 
  
Figure 2 
Bulk reduction of H4K16 acetylation in MSL3 patient cells  
(a) Immunohistochemistry of FFPE-skin sections for H4K16ac (white, MERGE in 
red) and E-cadherin (green). DAPI staining in blue. Asterisks highlight cells with 
reduced H4K16ac staining. Scale bar=20 µm. The staining was repeated twice with 
similar results. (b) as in a) but for MOF (white) (c) Immunostaining of ctrl, p1, p2 and 
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p14-derived primary dermal fibroblasts (HDFs) for H4K16ac (red) and MSL3 (white). 
Scale bar=10 µm. The staining was repeated twice (n=2 sections per slide). (d,e). 
Quantification of staining intensities for H4K16ac (d) and H3K27me3 (e) of one 
representative experiment in ctrl, p1, p2 and p14 HDFs. Each data point corresponds 
to the intensity of a single cell with the center line representing the average±SEM. p-
values were determined by Ordinary One-way ANOVA followed by Bonferroni 
multiple corrections. (f) Cropped immunoblot of HDF nuclear extracts. 100% and 
50% dilutions were loaded. The experiment was reproduced three times. (g) Volcano 
plot of indicated histone modification abundance displayed as log2FC (x-axis, p1, p2 
and p14 HDFs (n=6, 2 for each patient) in comparison to ctrl HDF (n=3)) versus the 
statistical significance (y-axis, two-sided moderated t-test) as determined by LC-MS.  
Vertical dashed lines represent 4-fold changes and a horizontal line shows a q-value 
-log101.2, Benjamini-Hochberg-corrected (BH) FDR=0.05. Circles in red=acetylated 
sites, violet=monomethylated sites, light-blue=propionyl-methylated sites, dark 
blue=trimethylated sites. Detailed results of statistical analyses in (d)-(e) are 
provided in Supplementary Table 5, for (g) in Supplementary Table 2.  
 
Figure 3 
Loss of MSL3 leads to transcriptome misregulation of developmental 
pathways 
(a) (Left) Heatmap representing z-scores of DE-genes (p1/p2/p14 vs ctrl) obtained 
by RNA-seq (FDR 0.05). (Right) MACS2 ChIP-seq21 peaks for mMSL1, mMSL2 and 
mMOF at mouse orthologues of MSL3 patient DE-genes illustrated with green, white 
(no peak), or grey boxes (no orthologue). (b) DE-genes pie chart. (c) Box plot 
displaying DESeq2 log2FC SEM for the DE-downregulated (n=196) versus the DE-
upregulated genes (n=323). The p-value was calculated using a two-sided Welch 
Two Sample t-test. (d) ChIP-seq peak frequency plot for mouse mMSL2 or 
mKANSL3 at unaffected/not-DE versus misregulated/MSL3-DE-genes in patients. P-
values for ChIP-peak over-representation or under-representation within the groups 
were calculated using a one-sided Fisher's test. (e) Dot plots (center line 
representing the average±SEM) of expression and H4K16ac ChIP qPCR analyses. 
Expression levels were determined in ctrl and patients (left) and upon MSL3 knock-
down (KD, middle) in male (♂) and female (♀) ctrl HDFs. H4K16ac ChIP-qPCR 
enrichment values were calculated relative to input and expressed as fold-change 
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over KLK3. (Right) Genome-browser snapshots of mMSL2 ChIP-seq enrichment at 
corresponding mouse orthologues (f) RT-qPCR expression analysis displayed as 
dotplots with center line representing the average±SEM. Expression levels were 
normalized to RPLP0 and expressed relative to ctrl. p-values were determined by 
Ordinary One-way ANOVA followed by Bonferroni multiple corrections. (g) IPA z-
score plot for Disease and Function signature of KEGG pathways (padj<0.005 
cutoff). BH multiple testing correction was applied (n=519 DE-genes). (h) Bubble plot 
representing perturbation pathway analysis for molecular and cellular functions. 
Bubble size=Molecule abundance, Color=IPA z-score. The most representative sub-
pathway by number of molecules was selected to represent the full signature (n=477 
transcripts). (a)-(f) In dotplots, each dot represents an independent experiment in 
HDFs. Further details and statistical test values of each plot are provided in 
Supplementary Table 5.  
  
Figure 4 
HDAC inhibition alleviates cellular and molecular phenotypes of MSL3 patient 
cells 
(a) MSL3 and empty expression vector (EV) were transfected in ctrl and p1/p14 
HDFs. Dot plots depict RNA levels of each independent experiment normalized to 
RPLP0 relative to EV with center line representing the average (n=2). (b) 
Immunofluorescence for H4K16ac (red) and MSL3 (green) upon treatment with 4 µM 
LBH-589. Scale bar=5 µm. The staining was reproduced twice. (c) Quantification of 
(b). Data points represent H4K16ac intensities of individual cells from one 
representative experiment with center line representing the average±SEM. p-values 
were determined by Ordinary One-way ANOVA followed by Bonferroni multiple 
corrections. Detailed results of statistical analyses are shown in Supplementary 
Table 5. (d) Heatmap of activation z-scores (z) obtained from IPA (Comparison 
Analysis, Disease and Function signature, (n=3391 ctrl, n=2740 p1, n=2487 p2, 
n=2737 p14 with padj<1E-4 DE-genes upon LBH-589 treatment (2 µM)). Activated 
pathways were plotted for |±z|>2.5 and p-value cutoff of log101.5. Bold highlights 
pathways impacting on patient cell physiology. (e) Heatmap representing z-scores of 
DE-genes reverting to not-DE anymore upon LBH-589 treatment (n=109). Five 
disease-relevant transcripts are highlighted. (f) IPA comparison analysis of KEGG 
pathway z-scores in genes rescued upon LBH-589 (n=109 with expression cutoff of 
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log ratio>|±0.2|). (g) Representative DIC images of HDFs at 0 and 24h after creating 
a “scratch” (gap area). (h) Quantification of the % gap area at 0h, 6h, 24, 48 hours 
for ctrl and patient HDFs grown with or without LBH-589 (2 µM). The center line 
represents the average±SEM (n=3).  
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Table 1 
 
 
MSL3 variants identified in the 16 reported individuals of this study. 
NA: Not available. 
 
  
 Genomic position hg19 
cDNA 
NM_078629.3 
Protein   
Q8N5Y2-1 Inheritance 
Patient 1 chrX:g.11790375G>T c.1381+1G>T NA de novo 
Patient 2 chrX:g.11790367_11790374del c.1374_1381del p.(Leu459Glufs*13) de novo 
Patient 3 chrX:g.11783713C>T c.1036C>T p.(Gln346*) de novo 
Patient 4 chrX:g.11783600T>C c.923T>C p.(Leu308Pro) de novo 
Patient 5 chrX:g.11790365C>T c.1372C>T p.(Arg458*) de novo – Parental mosaicism 
Patient 6 chrX:g.11790365C>T c.1372C>T p.(Arg458*) de novo – Parental mosaicism 
Patient 7 chrX:g.11780349_11780350delAC c.566_567delAC p.(Tyr189Leufs*3) de novo 
Patient 8 chrX:g.11783695delG c.1018delG p.(Ala340Leufs*9) de novo 
Patient 9 chrX:g.11783615dupC c.938dupC p.(Leu314Phefs*18) de novo 
Patient 10 chrX:g.11783802_11783818dup17 c.1125_1141dup17 p.(Met381Argfs*30) de novo 
Patient 11 chrX:g.11783850T>G   c.1171+2T>G N/A de novo 
Patient 12 Del exon 10 . . de novo 
Patient 13 chrX:g.11781990C>T c.841C>T p.(Gln281*) de novo 
Patient 14 chrX:g.11633731_11797224del . .  de novo 
Patient 15 chrX:g.11600773_12249902del . . NA – Father not tested, absent in the Mother 
Patient 16 Inv(X)(p22.2q28) . . Inherited from the mother – de novo in the mother 
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Online Methods 
  
Subjects, whole-exome sequencing and variant validation 
Sixteen individuals from 15 unrelated families with a disease-causing variant in 
MSL3 were included in this study after obtaining informed consent. The local ethic 
committee of the Dijon University Hospital approved this study (2016-A01347-44). 
The patients were followed-up by clinical geneticists from France, United Kingdom, 
the Netherlands, Belgium, Denmark, Germany, the US, Estonia and Australia. 
Thirteen variants were identified by whole-exome sequencing for the diagnostic of an 
undiagnosed rare disorder associated with multiple congenital anomalies and 
syndromic intellectual disability (ID), two deletions were identified by array-CGH and 
SNP-array, and the X chromosome inversion breakpoint in MSL3 was mapped by 
FISH and cloning of the junction fragment. The clinical observations were gathered 
through the Matchmaker Exchange initiative. 
Blood or DNA samples from affected individuals and their parents, and informed 
consent were obtained from all participants in accordance with site-specific 
institutional boards of each country. Dedicated consents for the collection of a skin 
biopsy was obtained. 
De novo variants were analyzed by PCR and direct Sanger sequencing using DNA 
from patients and their parents. Primer sequences and detailed methods are 
available on request. In the family with two affected siblings (p5 and p6) and 
suspected parental somatic mosaicism, confirmation and estimation of the 
percentage of cells bearing the variant was performed using DNA extracted from 
peripheral blood and saliva of all members of the family (the two patients and 
parents). Targeted sequencing for the variant position was performed on a MiSeq 
instrument (Illumina), at a depth of 1706 and 1398 folds for the variant position in the 
father and mother, respectively. Genotyping identified 12 and 6 variant alleles, 
resulting in an allelic balance of 0.007 and 0.004, respectively. In p1, the splice 
variant analysis was conducted on total RNA extracted from peripheral blood with 
TRIzol (Life Technologies). Sanger sequencing confirmed the splicing defect. Written 
consent was obtained from the parents and/or guardians of the affected individuals 
both for participation in the study and for use of the clinical photographs in this 
report. 
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Enrichment of de novo MSL3 variants in the matchmaker cohort 
The statistical significance after Benjamini–Hochberg correction for enrichment of 
functional and/or LoF de novo mutations in the matchmaker cohort was estimated as 
previously described in53. The gene-specific mutation rates were published in54. 
Because MSL3 is X-linked, we assumed that the matchmaker cohort had an 
equivalent proportion of males and females (5000 each, 15000 alleles). The 
uncorrected p-value was corrected for multiple testing taking 18280 genes to apply 
the Benjamini-Hochberg False Discovery Rate correction. 
  
Exome analysis 
Each collaborating team followed a published methodology for sample and library 
preparation, sequencing data production, analysis and interpretation55–59. 
  
Parental segregation analysis 
Genomic DNA was amplified by Polymerase Chain Reaction (PCR) using 
HotStarTaq PCR kit (Qiagen). PCR products were purified by Agencourt CleanSEQ 
system (Beckman Coulter) and sequenced with the BigDye Terminator Cycle 
Sequencing kit, v3.1 (Applied Biosystems) on ABI 3730 sequencer (Applied 
Biosystems). Sequence data were analyzed using Mutation Surveyor v4.0.9 
(Softgenomics). 
  
MiSeq cDNA analysis 
Total RNA was extracted from peripheral blood with TRIzol (Life Technologies). The 
integrity of the RNA was assessed on 1.2% agarose gel, and the concentration and 
purity was determined by optical densitometry. cDNA was generated with the 
QuantiTect Reverse Transcription Kit (Qiagen) and PCR amplified (Supplementary 
Table 5) with PrimeStar GXL (Takara). Nextera XT DNA Preparation kit (Illumina) 
was used to create a cDNA library and sequenced on a Miseq instrument (Illumina). 
Resulting data were aligned to the human reference genome (GRCh37/hg19) using 
STAR2 (v2.5.3)60. Aligned reads were sorted using Picard (v2.17). Splice junctions 
and transcript organization were visualized using the sashimi plot of the Integrative 
Genomics Viewer. 
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Haplotype 
The MSL3 locus was amplified from genomic DNA by long range PCR using 
PrimeStar GXL (Takara). PCR products were pooled for each case. Nextera XT DNA 
Preparation kit (Illumina) was used to create a tagged and fragmented DNA library, 
which was sequenced on a MiSeq (Illumina). Resulting data were aligned to the 
reference genome (GRCh37/hg19) using BWA (Burrows-Wheeler Aligner; v0.7.6). 
The Genome Analysis Toolkit (GATK; v2.1-10) enabled indel realignment and base 
quality score recalibration. Variants with a quality score >30 and alignment quality 
score >20 were annotated with SeattleSeq SNP Annotation (v137). Haplotype was 
determined using HaplotypeCaller from VCF files. 
  
Protein modeling 
The complex structure of the MSL1-MSL3 complex (PDB: 2Y0N) was analyzed and 
visualized with Pymol (v1.7.4) 
        
Cloning for protein expression and purification 
The human MOF174-458 and MOF2-458 (Uniprot: Q9H7Z6-1) coding sequences (CDS) 
were cloned in a modified pET15b vector (His10tag). MSL1470-520 or MSL1471-616 
(Uniprot: Q68DK7-1) and MOF174-458 (MCS2) CDS were cloned in a pACYC 
coexpression vector (Novagen, MCS1: MSL1470-520 or MSL1471-616; MCS2: MOF174-
458). The CDS of MSL3167-517 (Uniprot: Q8N5Y2-1) was cloned in MCS1 of a modified 
pRSFDuet vector. Proteins were expressed in LB using Rosetta2 pLysS (MOF174-458, 
MOF2-458) or BL21(DE3) cells (MOF174-458-MSL1470-520, MOF174-458-MSL1471-616-
MSL3167-517). Expression was induced with IPTG (0.1-1 mM, OD600 0.5-0.7, 18 °C 
overnight). After lysis by sonication (MOF174-458, MOF174-458-MSL1470-520, MOF174-458-
MSL1471-616-MSL3167-517: 50 mM HEPES, 500 mM NaCl, 20 mM imidazole, 5 mM 
beta-mercaptoethanol, 0.01 % (w/v) taurodeoxycholate, 1 EDTA-free cOmplete 
(Roche), pH 7.5; MOF2-458: 50 mM HEPES, 100 mM NaCl, 20 mM imidazole, 5 mM 
beta-mercaptoethanol, 0.01 % (w/v) taurodeoxycholate, 1 cOmplete (Roche), pH 
7.5), and clarification by centrifugation, the supernatant was applied to a HisTrap HP 
column (GE Healthcare). This was washed with lysis buffer (for  MOF174-458, MOF174-
458-MSL1471-616-MSL3167-517 containing 2000 mM NaCl) before elution with an 
imidazole gradient (20-300 mM). Protein containing fractions were pooled. 
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After buffer exchange (50 mM HEPES, 100 mM NaCl, 20 mM imidazole, 5 mM beta-
mercaptoethanol, 0.01 % (w/v) taurodeoxycholate, pH 7.5), the solutions containing 
MOF2-458 and the trimeric MOF complex were applied to a Heparin HP column (GE 
Healthcare) and eluted with a NaCl gradient (100-2000 mM NaCl). Protein-
containing fractions were pooled and concentrated. Finally, MOF174-458, MOF2-458, 
MOF174-458-MSL1470-520 or MOF174-458-MSL1471-616-MSL3167-517 were applied to a 
Superdex S75 (MOF174-458, MOF2-458, MOF174-458-MSL1470-520) or S200 (MOF174-458-
MSL1471-616-MSL3167-517) gel filtration column (25 mM HEPES, 500 mM NaCl, pH 
7.5). Protein-containing fractions were pooled, concentrated, flash-frozen and stored 
at -80 °C. Chromatography was performed on Äkta purifier systems. The purity of all 
assayed proteins and complexes was > 90 %. Protein concentration was determined 
by Bradford assay. 
  
Nucleosome reconstitution, histone acetyltransferase assays 
Nucleosomal core particles (NCP) were reconstituted using a PCR-amplified 147 bp 
DNA fragment61 with 5’ Cy5 and 3’ Biotin and Xenopus laevis histone octamers 
applying salt dialysis62. NCP quality was assessed using agarose gel 
electrophoresis. For histone acetyltransferase assays, 100 nM MOF174-458, MOF2-458, 
MOF174-458-MSL1470-520, or MOF174-458-MSL1471-616-MSL3167-517 were mixed with 
AcCoA (Sigma, final concentration 33 µM), and nucleosomes (0.54 µg) in assay 
buffer (10 mM Tris, 200 mM NaCl, 1 mM EDTA, pH 8.0) and incubated for 1 h (37 
°C, 600 rpm). The reaction was stopped by addition of 4xSDS sample buffer followed 
by SDS-PAGE and immunoblot. 
  
Cell culture, drug treatment and transfections 
Primary HDFs were isolated from 3 mm skin biopsies using 0.25% Collagenase type 
I, 0.05% DNase I, 20% FCS high glucose DMEM (Gibco) overnight at 37°C. Dermal 
fibroblasts were let to attach and cultured in DMEM supplemented with 10% FCS 
pen-strep. All experiments were performed at early passages (2 to 8). LBH-589 
(Selleck Chemicals Co. Ltd.), MGCD0103 (Toronto Research Chemicals), SAHA 
(Adipogen), TSA were dissolved in DMSO. For most experiments, prior to 
experimental treatment, cells were starved overnight in HBSS medium (24020133, 
Thermo Fisher). Flp-In 293 T-REx cells (R78007, Thermo Fisher) were maintained in 
DMEM-Glutamax supplemented with sodium pyruvate, glucose and 10% FBS. They 
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were also maintained in zeocin- and blasticidin-containing medium according to the 
manufacturer’s protocol. All transgenes used in immunoprecipitation experiments 
were cloned into pCDNA5-FRT/To (V6520-20, Thermo Fisher) with a C-terminal 
3XFlag–HBH. MSL1 CDS was cloned with a C-terminal 3xHA-Avi tag. This vector 
was co-transfected with MSL3 WT (full length=fl), truncating mutants or with GFP 
CDS (as a IP negative control) in 1:1 ratio (500 ng each on 6 well plates for nuclear 
FLAG-IPs) with a 3:1 Lipid (µl of Lipofectamine 2000) to DNA (µg) ratio. 6 hours after 
transfection, transgenes were induced with 0.1 µg/ml Doxycyline for 16 hours before 
lysate preparation. The hsMSL3-3xFlag-HBH CDS was subcloned into a custom 
pCAG-MCS-BGH(polyA), pSV40-BlasticidinR-SV40(polyA), pSV40-mCherry-
SV40(polyA) vector created in multiple steps from SV40 promoter containing 
backbone pMB1610 (addgene 65853). The vector and map can be provided upon 
request. For HDF transfections, 0.1 µg plasmid was used with Lipofectamine 3000 
on 1x105 cells in OPTI-MEM followed by selection with 30 µg/ml blasticidin-HCl 
(Invitrogen A111139-03) overnight. Cells were then grown in fresh media for 24h 
before RNA extraction. 
  
FLAG-immunoprecipitation (IP) 
Nuclei were isolated with 0.5% NP-40 in isotonic lysis buffer (10 mM Tris HCl, pH 
7.5, with 2 mM MgCl2, 3 mM CaCl2, 0.3 M Sucrose). Nuclear pellet was extracted 
using HMGT buffer (25 mM HEPES pH 7.5, 10 mM MgCl2, 10% glycerol, 0.2% 
Tween-20) containing 420 mM KCl. The lysate was clarified by centrifugation before 
slowly reducing KCl to 150 mM by dilution.  FLAG-M2 beads (Sigma 1804) were 
used for overnight IP followed by HMGT buffer (150 mM KCl) washes. Proteins were 
eluted by incubating 10 minutes at 70ºC in 2xSDS sample buffer. 
  
MSL3 knock-down in HDFs 
Silencer Select (Ambion-Thermo Fisher) siRNA ID s21530 and control siRNA were 
used at a final concentration of 50 nM for 32 hours before RNA extraction. 
  
Expression analysis in HDFs and RT–qPCR 
Total RNA was prepared from 12-well plate cultured cells using TRIzol (Thermo 
Fisher) and purified with Direct-zolTM RNA MiniPrep and MicroPrep kits (Zymo 
Research). cDNA samples were synthesized using Maxima Reverse Transcriptase 
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(K1671, Thermo Fisher) from 20-50 ng of total RNA. RT–qPCR reactions were 
performed on a LightCycler® 480 Multiwell Plate 384 (Roche) using SYBR Green 
Master Mix (Roche). Primer efficiency was tested using serial dilutions. 
  
Immunofluorescence and Immunohistochemistry 
HDFs were seeded as required for the experimental setup and fixed in 4% 
formaldehyde in µ-Slide 8-well on ice.  FFPE-section and HDFs immunostainings 
were performed according to published procedures63 using MSL3 antibody 
(USBI129933, MaxPab, 1:200) as primary together with H4K16ac (07-329, Millipore, 
1:500), H3K27me3 ((C36B11) 9733, Cell signalling, 1:250), E-cadherin (610181, BD 
Bioscience, 1:200),  KAT8 [EPR15803] (ab200660, Abcam, 1:500) antibodies. 
Multi-stacked and tailed images were acquired on a Spinning disk confocal 
microscope (Zeiss). Fluorescence intensity was measured on orthogonal projections 
from the same stack number using ImageJ (1.47v) and corrected for background. 
Fluorescently-labeled secondary antibodies (Invitrogen) were used at 1:300 dilution: 
goat-anti-mouse-Alexa594 (A-11032), goat-anti-rabbit-Alexa594 (A-11037), goat-
anti-rabbit-Alexa488 (A-11034), goat-anti-mouse-Alexa488 (A-11001). 
  
Immunoblotting 
Cells were fractionated using a subcellular fractionation kit (78840, Thermo Fisher), 
the buffers supplemented with cOmplete (Roche) and sodium butyrate (19-137, 
MerckMillipore). Protein concentration was determined using Qubit protein assay 
reagent. Samples were denatured at 95 °C for 10 minutes in Pierce™ Lane Marker 
Reducing Sample Buffer, resolved by NuPAGE Bis-Tris denaturing conditions, 
transferred to 0.22 µm PVDF membranes followed by blocking in 5% nonfat milk in 
PBS (0.3% Tween) before incubation with antibodies: MSL3 (USBI129933, MaxPab, 
USBiologicals, 1:1000 in BSA), H3 (61475, Active Motif, 1:5000), H4K16ac (39167, 
Active Motif, 1:2000; 07-329, Millipore, 1:2000), Flag (M2, Sigma, 1:1000), HA 
(MMS-101P, Covance, 1:1000), MOF (A300-992A, Bethyl, 1:1000), DHX9 (NDH-
II(E10) sc-137183, 1:2000-1:5000), H3K36me3 (ab9050, Abcam, 1:1000), acH3 
(rabbit, Millipore, 1:1000), H4K20me1 (ab9051, Abcam, 1:1000), H4K8ac (61103, 
Active Motif, 1:1000), H3K14ac (39599, Active Motif, 1:1000), acH4 (06-598, 
Millipore, 1:1000), H3K27me3 (9733, Cell Signaling, 1:1000). 
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Mass Spectrometry sample preparation 
After histone extraction (78840, Thermo Fisher), proteins were separated on a 16 % 
Tris-Glycine gel (Novex™) and stained with colloidal coomassie. Gel bands 
containing histones were cut out. After destaining, reduction and in gel alkylation, 
histones were propionylated in a 79:1 mixture of isopropanol and propionic 
anhydride (240311, Sigma) for 2h. Gel pieces were washed with MiliQ water, dried in 
a SpeedVac centrifuge and rehydrated in hydroxylamine followed by incubation with 
ammonium hydroxide solution to reestablish neutral pH. After further washes with 
ammonium bicarbonate-based buffer and acetonitrile, gel pieces were again 
dehydrated. Subsequent tryptic digestion was performed as described in64. 
Recovered peptides were desalted on STAGE tips according to65. 
  
LC-MS bottom-up analysis of histone peptides 
Digested and desalted peptides were analyzed by LC-MS/MS using nanoflow HPLC 
(Easy nLC1200, Thermo Fisher) coupled with QExactive hybrid mass spectrometer 
(Thermo Fisher) through a nanoelectrospray ion source (Proxeon). Peptides were 
loaded on a 20 cm long, 75 µm wide analytical column filled in-house with 1.9 µm 
C18 beads (Reprosil C18, Dr. Maisch GmbH, Germany) at a flow rate of 500 nl/min. 
Analytical column was then equilibrated for 5 minutes (5% buffer A) which was 
followed by a 60 minutes long peptide elution at flow rate of 300 nl/min with a linearly 
increasing concentration of organic solvent (80% acetonitrile, 0.1% formic acid). 
QExactive was operated in positive mode, employing data-dependent acquisition of 
fragmentation spectra of multiple-charged peptides for their identification. 
MaxQuant software (v1.6.0.16) was used for raw file peak extraction and protein 
identification. Peptide and protein False Discovery Rate (FDR) was set to 0.01 using 
a decoy database. Additionally, “match between runs” was used with matching time 
window of 1 minute and alignment time window of 20 minutes. 
  
LC-MS data analysis 
List of ratios of modified lysine or arginine sites derived from MaxQuant (“…sites.txt”) 
was imported to Perseus66. Data matrix was modified by applying “Expand site table” 
step, removing empty rows, as well as contaminants and entries from decoy 
database. All site intensities were log2 transformed and normalized by subtracting 
the mean of the whole sample from the particular histone site intensities67. A 
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moderated t-test was used to test for significant differences between control and 
patient samples. Differences with a qvalue<0.05 (Benjamini-Hochberg corrected) 
were considered as significant. 
  
Paraffin embedding and sectioning 
2mm human skin specimens were fixed overnight in PBS containing 4% 
formaldehyde. After dehydration in ethanol/PBS and Histolemon series, they were 
incubated in paraffin at 58°C overnight and casted into molds covered with paraffin. 
Blocks were sectioned using an RM2155 microtome (Leica) at 5-10 µm. Additional 
FFPE skin sections age-matching to ctrl were purchased from BioCat. 
  
Hematoxylin and Eosin (H&E) staining 
Paraffin sections were dewaxed and rehydrated step-wise. The samples were 
stained in hematoxylin solution (0.1% hematoxylin, 5% KAl(SO4)2, 0.02% KIO3). 
Counterstaining was performed by incubating the slides in eosin solution (1% eosin). 
Slides were mounted in Permount Mounting Medium (Thermo Fisher) and analyzed 
using brightfield microscopy. 
  
Cell cycle analysis by FACS 
HDFs were synchronized by mitotic shake followed by serum starvation overnight. 
Cells were induced to cycle for 6 hours by addition of complete media. 1x106 HDFs 
were fixed in suspension in 70% cold ethanol while gently shaking for 20 minutes at 
4°C. After washing in FACS buffer (0.2% BSA in PBS), H4K16ac staining was 
performed at RT for 90 minutes (39167, Active Motif, 1:500; 07-329, Millipore, 1:500 
in FACS buffer). This was followed by 30 minute incubation with Ki67-FITC as 
indicated (BD Biosciences, 556026) and 2ndary anti-rabbit (APC labeled). Propidium 
iodide (PI) (1 µg/ml) was used to stain nuclei. After additional washes, cells were 
analysed in FACS buffer using LSRII (BD, Heidelberg, Germany). 
Alive singlets, based on FSC/SSC, were gated for further analysis. Three channel 
analyses were performed using antibodies/dyes with no fluorescence absorbance 
overlap. Machine Laser intensities were set up using beads. For downstream 
analysis in FlowJo (v10.4.1), alive cells were gated, followed by re-gating of only 
single cells. For cell cycle phases analyses, “Cell cycle” automatic function was run 
using PI. 
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Colorimetric Detection of Senescence-Associated β-Galactosidase 
Performed as described in68. Pictures were taken with a conventional CCD camera 
on a regular inverted cell culture microscope with a 10x objective. 
  
RNA-seq 
Approximately 50 ng RNA was isolated from synchronized ctrl, p1, p2 and p14 HDFs 
at passage 4 and passage 7 and subjected to poly(A) RNA-seq (TruSeq® Stranded 
mRNA Sample Preparation kit, Illumina). Reads were mapped to the GRCh37/hg19 
reference genome with HISAT2 (v2.2.0-beta)69 using default parameters. Primary 
alignments were assigned to features with featureCounts (v1.4.6-p2)70 using the 
GRCh37 Gencode annotation (release 19). Differential expression (DE) analysis was 
performed using DESeq2 (v1.18.1)71 with default settings. We identified DE-genes 
between control and all patients with patients treated as biological replicates at FDR 
adjusted P<0.05 (ctrl vs. p1/p2/p14). When LBH-589-treated patients were compared 
to DMSO-treated controls (FDR<0.05), we considered previously identified DE-
genes as “rescued” if they were not differentially expressed anymore. To assess the 
global effect of LBH-589, genes were identified as DE in DMSO vs. LBH-589 
treatment, irrespective of the cell line, at FDR adjusted Padj<0.001. Network maps 
and pathways/cell components were generated in Ingenuity Pathway Analysis (IPA, 
Qiagen Redwood City, Version 01-07 (01-07)), using curated lists from Ingenuity 
Pathways Knowledge Base. Activation z-scores were used to infer the activation 
states (“increased” or “decreased”) of implicated biological functions.  Differentially 
expressed genes were annotated using the OMIM morbid map (version November 
2017). 
  
ChIP-seq analysis 
MACS2 ChIP-seq peaks of mMSL2, mMOF and mKANSL321 were split in TSS (gene 
overlapping within ± 1kb of the TSS), gene body (gene overlapping from TSS+1kb 
until gene end) or distal (closest gene to any peak) groups based on the NCBIM37 
Gencode annotation (v1) and compared to the DE-genes in MSL3 patients. Mouse 
orthologues of MSL3-DE genes were identified on Ensembl BioMart. Overlaps, 
frequency calculations, statistical analyses and plots were generated in R (Version 
1.1.383). 
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Scratch assay of HDFs 
Equal number of cells were seeded in Culture insert-2 (IBIDITM) in 12 wells and let to 
attach. Cells were starved overnight before adding fresh media with LBH-589 (2 µM) 
or DMSO. The cell-free gaps in which the cell migration can be visualized was 
created by removal of the silicon comb. Pictures were taken with a conventional 
CCD camera on a regular inverted cell culture microscope with a 10x objective at 0, 
6, 24 and 48h after removal of the comb and drug administration. Images were 
analysed using ImageJ (1.47v) measuring the cell-free gap and plotted as ratio over 
time 0 for each corresponding cell line. 
  
H4K16ac Chromatin Immunoprecipitation (ChIP) 
HDFs were starved overnight and collected by centrifugation after cell counting. 
Cells were crosslinked using 1% formaldehyde for 10 minutes.  Sodium Butyrate was 
added to all buffers. Cell were fractionated (78840, Thermo Fisher) and nuclei 
dissolved in lysis buffer (20 mM Tris pH 8, 5 mM MgCl2, 1 mM CaCl2, 0.25 M 
Sucrose, 1% Triton-X100, 10 µM EDTA, 0.5% SDS). 50’000 lysed nuclei were 
diluted with 5X dilution buffer (10 mM Tris-HCl pH8, 140 mM NaCl, 0.1% 
NaDeoxycholate, 1% Triton-X100, 1 mM EDTA, 1x protease, 0.1% SDS) and 
chromatin sheared using a Diagenode Bioruptor Pico (7 cycles with 30 sec ON/OFF. 
IP timing and antibody concentration were tightly set up using Flow cytometry 
(50’000 nuclei, 2 hours, RT, 1:750 dilution). DynaBeads-bound chromatin was 
washed using 2x IP dilution buffer, 1x High Salt wash buffer (400 mM NaCl), 1x LiCl 
buffer and 1x TE. Chromatin was reverse crosslinked at 65°C overnight followed by 
RNAseA and Proteinase K digestion. DNA was purified using phenol-chloroform 
extraction followed by Ethanol precipitation. 
  
Statistics 
All statistics were calculated with GraphPad Prism 6/7 or R (v1.1.383). One-way-
ANOVA was performed for multiple comparisons followed by Bonferroni corrections 
for individual pairing. Dot plots are presented with center line as average±SEM. In 
the box plots in Figure 3c and Supplementary Figure 2e, the line that divides the box 
into 2 parts represents the median, the ends the upper and lower quartiles (first and 
third quartile). The extreme lines shows the highest and lowest value excluding 
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outliers. Bar plots represent the average±SEM with overlaid data points representing 
independent experiments. Results were considered significant at FDR (p-value) 
below 5%. ns: not significant. NA: not analyzed. SEM: standard error of the mean. 
Additional informations and test results of statistical analysis are provided in the 
Figure Legends and Supplementary Table 5. 
  
Web Resources 
NHLBI Exome Sequencing Project Exome Variant Server: 
http://evs.gs.washington.edu/EVS/ 
dbSNP: http://www.ncbi.nlm.nih.gov/projects/SNP/ 
Picard: www.picard.sourceforge.net 
University of Burgundy Centre de Calcul, https://haydn2005.u-bourgogne.fr/dsi-ccub/ 
Seattle Seq Annotation tool: snp.gs.washington.edu/SeattleSeqAnnotation137/ 
ExAC browser: http://exac.broadinstitute.org/ 
GATK, HaplotypeCaller: 
https://www.broadinstitute.org/gatk/gatkdocs/org_broadinstitute_gatk_tools_walkers_
haplotypecaller_HaplotypeCaller.php 
EBI Expression Atlas: https://www.ebi.ac.uk/gxa/home/ 
Ensembl Biomart: https://www.ensembl.org/biomart/ 
Integrative Genome Viewer: https://software.broadinstitute.org/software/igv/ 
  
Reporting Summary 
Further information on experimental design and reagents can be found in the Life 
Sciences Reporting Summary. 
  
Data availability 
RNA-seq data have been deposited to the Gene Expression Omnibus under the 
accession number GSE102250. 
The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the 
PRIDE partner repository72 with the dataset identifier PXD009317. 
The damaging variants reported as disease-causing in this article were deposited in 
ClinVar database under study accession SUB2871008. 
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Supplementary Figure 1 
MSL3 variants cause a novel syndrome 
(a) Representation of the MSL3 patient countries of origin. (b) Sanger sequencing confirming the skipping of MSL3 exon 11 in p1 
cDNA. The allelic ratio was in favour of random X inactivation. Right: Cropped agarose gel picture of RT-PCR products. (c) Schematic 
representation of X-chromosome inversion of p16. (d) Patients pedigrees. No MSL3 variant could be detected in the parents of patients 
p1-11 (the father of patient p10 could not be tested). p16’s mother is reported as mildly affected with no clinical details provided. Her X 
chromosome inversion occurred de novo.  (e) Heatmap representing RNA-seq data for MSL3 in the developing human brain compared 
to other members of the MSL complex. Data was retrieved from https://www.ebi.ac.uk/gxa/home/ (f) Amino acid sequence alignment of 
MSL3 orthologues showing that the mutated residues are highly conserved throughout evolution. 
 
 
 
 
 
Supplementary Figure 2 
Characterization of MSL3 patient-derived fibroblasts 
(a) FFPE-skin sections from ctrl and p1/p2/p14 stained with H&E. Dashed line distinguishes dermis and epidermis layers. Architectural 
skin layers are demarcated. Scale bar=20 µm. Patients donated n=1 skin sample, at least two sections per slide were analysed. 
SB=Stratum Basale, SL= Stratum lucidum, SS=Stratum Spinosum, SC=Stratum Corneum (b) Immunostaining for H3K27me3 (red) in 
primary dermal fibroblasts (HDFs). Scale bar=5 µm. The staining was repeated twice with similar results. (c) Cropped immunoblot for 
H4K16ac, total Histone H3, as well as H3 and H4 pan-acetylation in additional HDF lines. The experiment was repeated twice with 
similar results. (d) Sashimi plot derived from MiSeq results showing exon skipping in p1, but not p2 or ctrl HDF cDNA. (e) Distribution of 
identified protein intensities measured in LC-MS/MS experiments before (left) and after normalization (right). Protein intensities as well 
as modified site intensities were normalized and scaled by adjusting the centers of the distributions around zero to account for loading 
differences in SDS-PAGE. Box plots are centered in the median with the lower and upper hinges corresponding to the first and third 
quartiles. Normalized values were used for further statistical analysis as described in Supplementary Table 2. (f) Heatmap representing 
all acetyl (K), mono and tri-methyl (R-K) histone modifications normalized intensities detected over bulk histone background level as in 
Supplementary Table 2. (g) Proliferation curve in p1, p2 and p14 compared to ctrl. The center value at each time point represents the 
average of n=2 independent experiments. (h) FACS cell cycle analysis of ctrl and p1/p2/p14 HDFs, Propidium Iodide was used to 
define cell cycle phases. Bar plots represents average of n=2 independent experiments with overlaid data points. (i) RT-qPCR analysis 
of senescence markers P16-INK4A and P21-WAF displayed as dot plots. Expression levels were normalized to RPLP0 and expressed 
relative to ctrl. Each data point represents an independent experiment (n) with center line representing average±SEM when applicable. 
p-values were determined by Ordinary One-way ANOVA followed by Bonferroni multiple corrections. Further details and statistical test 
values are provided in Supplementary Table 5. (j) Representative DIC images of β-galactosidase activity assay performed in ctrl and 
p1/p2/p14 HDFs. The experiment was repeated 3 times with similar results. (k) Representative FACS analysis of MKI67 (x-axis) and 
H4K16ac (y-axis) in ctrl and p1/p2/p14 HDFs. Quadrants show % of cells with relative abundance of cell populations. The experiment 
was repeated twice with similar results.  
 
 
 
Supplementary Figure 3 
Validation of transcriptional responses in MSL3 patients 
(a) MA-plot comparing the mean of the normalized counts versus the log2FC obtained from RNA-seq of patients versus ctrl HDFs (n=2 
passages of ctrl were compared with n=2 passages of each p1, p2 and p14). DE-genes (FDR cutoff of 0.05) are marked in red. (b) 
H4K16ac ChIP qPCR analysis of H3F3B and respective expression levels from RNA-seq (normalized read counts) displayed as dot 
plots. H4K16ac ChIP-qPCR enrichment values were calculated relative to input and expressed as a fold change enrichment over the 
negative control KLK3. Each data point represents an independent experiment (n) with center line representing average±SEM where 
applicable. (c) RT-qPCR expression analysis in HDFs displayed as dotplots. Expression levels were normalized to RPLP0 and 
expressed relative to ctrl. Each data point represents an independent experiment (n) with center line representing average±SEM where 
applicable. p-values were determined by Ordinary One-way ANOVA followed by Bonferroni multiple corrections. Further details and 
statistical test values are provided in Supplementary Table 5. (d) Immunohistochemistry for Serotonin receptor (HTR7) and Netrin 
 
 
receptor (UNC5B) on control and patient-derived FFPE-skin sections. Similar staining results were obtained in n=2 sections per slide 
(e) RT-qPCR expression analysis in male and female HDFs upon MSL3 knock-down (KD) displayed as bar plots representing the 
average±SEM. Expression levels were normalized to RPLP0 and expressed relative to scrambled siRNA. The same data points for 
ZNF185 and SPON2 are also shown in main Figure 3 and are illustrated again for comparative purposes. Each overlaid data point 
represents the number (n) of independent experiments. 
 
 
 
 
 
Supplementary Figure 4 
Response to HDACi in MSL3 patient cells 
(a) Heatmap representing histone modification changes upon HDACi treatments (dataset from Schölz et al., Nat. Biotechnol. 2015, doi: 
10.1038/nbt.3130). (b) Cropped immunoblot for H4K16ac, pan-acetylated H3 and H4, H3K27me3, H3K4me1 and H3 of nuclear extracts 
of ctrl HDFs treated with HDACi. The same extracts were separated on a coomassie-stained gel serving as loading control. The 
experiment was repeated twice with similar results. (c) RT-qPCR of acetylation-sensitive targets in ctrl HDF. The bar plot represents the 
average of n=2 independent experiments with overlaid individual data points. (d) Cropped immunoblot of p1/p2/p14 HDFs nuclear 
extracts upon LBH-589 treatment. The experiment was repeated twice with similar results. (e) RT-qPCR of p1/p2/p14 HDFs treated 
with four different HDACi: SAHA (vorinostat, HDAC class I and II inhibitor), LBH-589 (panobinostat, pan-HDACi) and MGCD0103 
(mocetinostat, HDACi class I and IV). Expression levels are normalized to RPLP0 and calculated relative to ctrl (without treatment) and 
shown as dot plots. Each data point represents (n) independent experiments with center line representing the average±SEM where 
applicable. (f) Scheme representing the number of DE-genes upon LBH-589 treatment. (g) Heatmap representing z-scores on the 
MSL3 patients DE-downregulated (left, n=196) and DE-upregulated (right, n=323) genes upon LBH-589 obtained by RNA-seq 
(p1/p2/p14, 2 passages). (h) Dot plots of normalized RNA-seq read counts for DNA damage and cell cycle marker genes before and 
after treatment with LBH-589. The center line represents the average of n=2 independent experiments. (i) Representative DIC images 
upon LBH-589 treatment of ctrl and p1/p2/p14 HDFs at 0h, 24h, 48h after creating a gap area. 
 
 
 
 
 
Supplementary Figure 5 
Uncropped western blots, agarose and coomassie gel pictures, and gating strategy example. 
To illustrate molecular weight markers, epi-white and chemiluminescence pictures were merged in the display (respective blots are 
marked with an asterisk). Actual figure panels represent only chemiluminescence and not the merged pictures. Cropped regions are 
framed. Representative gating strategy for excluding debris (upper), and doublets (lower) in flow cytometry analysis of 1×104 events. 
Singlets are defined on the Forward-Scatter (height) vs. Forward-Scatter (area) dot plot. !!
